Enabling you to identify and mitigate the intrinsic risk in your operations, supply chains and business processes.
Evaluating how your products and services meet and exceed quality, safety, sustainability and performance standards.
Validating the specifications, value and safety of your raw materials, products and assets.
Discovery phase bioanalysis including rapid screening, non-GLP bioanalysis tailored to support your early stage drug development and lead optimization
Intertek provides three 'standard' modes of LC-MS/MS bioanalytical support for drug discovery based upon your requirements. A dedicated LC-MS/MS discovery project team typically delivers data within 5 days after sample receipt, given one-week of advance notice.
Mode I - Rapid Discovery Screen
Mode II – Lead Optimization (non-GLP early Pharmacokinetic (PK) studies)
Mode III – Lead Qualification (bridging and non-GLP toxicokinetic studies)
Need help or have a question?